Chiesi has entered into a definitive agreement to acquire Kalvista Pharmaceuticals, and with it, Ekterly (sebetralstat), an oral on‑demand treatment for acute swelling attacks in people with hereditary angioedema (HAE). The transaction was approved by both companies’ boards of directors and is expected to be completed by the…